| 1.765 -0.085 (-4.59%) | 08-20 13:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.15 |
1-year : | 2.27 |
| Resists | First : | 1.84 |
Second : | 1.95 |
| Pivot price | 1.76  |
|||
| Supports | First : | 1.66 |
Second : | 1.38 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 1.76 |
| MA(100) : | 3.31 |
MA(250) : | 6.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 36.7 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 12.25 | Low : | 1.39 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENGN ] has closed below upper band by 44.2%. Bollinger Bands are 90.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 58 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.9 - 1.91 | 1.91 - 1.91 |
| Low: | 1.72 - 1.73 | 1.73 - 1.74 |
| Close: | 1.84 - 1.85 | 1.85 - 1.86 |
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Mon, 17 Aug 2026
enGene Holdings (ENGN) Edges Higher: Gene Therapy Stock Holds Key Support at $1.64 - Fast Moving Stocks - Vinanet
Fri, 14 Aug 2026
Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan
Fri, 14 Aug 2026
enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan
Thu, 13 Aug 2026
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - TradingView
Fri, 07 Aug 2026
enGene Holdings Inc (ENGN) Stock News Today - TradingKey
Wed, 29 Jul 2026
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 107.5 (%) |
| Shares Short | 1,640 (K) |
| Shares Short P.Month | 1,390 (K) |
| EPS | -2.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -52.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -110 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|